Peptide profile · Healing & Recovery

Relaxin-2 (Serelaxin)

Name: Relaxin-2 (Serelaxin) — Peptide Information
Creator: Michael Carroll

Recombinant human relaxin-2 studied for acute heart failure recovery and cardiovascular support

Written & reviewed by Michael Carroll · Research, Peptide Initiative

Healing & RecoveryLimited human trialsResearch compound

Typical dose

30 mcg/kg/day

Once dailyCycle: 8-12 weeksOnset: Moderate (1-2 weeks)

Half-life

Varies by route of administration

Bioavailability

Varies by route of administration

Molecular weight

5,963 Da (Daltons)

Evidence level

Limited human trials

01 · Compound profile

Scientific & efficacy data

Molecular formula

C₂₅₆H₄₀₈N₇₄O₇₄S₈

Primary benefits

Cardiovascular Function72

Supports improved cardiovascular function and hemodynamics

Heart Failure Support68

May improve symptoms and exercise capacity in acute heart failure patients

Acute Medical Management64

Potential to improve quality of life in heart failure management

Mol. weight5,963 Da (Daltons)

CAS numberSee PubChem for identifiers

PubChem71300755

Developed · Research ongoingAcademic research consortium
Multiple research institutions

Amino acid sequence

Sequence not publicly available or proprietary

02 · Dosing

How much do I take?

30 mcg/kg/day · continuous iv infusion

Intravenous: Delivered straight into a vein through a drip (IV), done by a clinician.

Bioavailability Complete (about 100%) — delivered straight into the bloodstream.

Standard30 mcg/kg/dayContinuous IV infusion · 48 hoursWeight-adjusted continuous IV infusion used across the RELAX-AHF programme for acute heart failure; improved dyspnea but did not reduce mortality in RELAX-AHF-2 [3][5]. Hospital administration only.

Best time to take

Administer at a consistent time each day. Consistency matters more than the specific time of day.

With food?

Food timing does not significantly affect absorption for injectable peptides.

If stacking

If combining Relaxin-2 (Serelaxin) with other peptides, space administrations by 15-30 minutes. Consult your healthcare provider before combining with prescription medications.

＋ Increase if

+Current dose is well-tolerated for 2+ weeks
+Desired effects not yet noticeable
+Healthcare provider recommends dose increase

－ Decrease if

−Side effects become bothersome or persistent
−Desired effects achieved at lower dose
−Healthcare provider recommends reduction

✓ Signs of right dose

✓Noticeable improvement in target symptoms
✓Good tolerance with minimal side effects
✓Consistent positive response between doses

Dosing Calculator

Calculate Your Exact Dose

Step 1: Peptide Weight

Find the weight printed on your peptide vial label

Look here!

The peptide weight is printed on the label

5mg

Look here!

The weight is on the label

5mg

Select Weight

Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)

03 · Suitability

Is this right for me?

Best for acute heart failure symptom management & cardiovascular recovery and support

Best for

Acute heart failure symptom management

Relaxin-2 (Serelaxin) is particularly effective for individuals focused on acute heart failure symptom management. Research supports its use in this area.

Cardiovascular recovery and support

Relaxin-2 (Serelaxin) is particularly effective for individuals focused on cardiovascular recovery and support. Research supports its use in this area.

Hospital-based therapeutic interventions

Relaxin-2 (Serelaxin) is particularly effective for individuals focused on hospital-based therapeutic interventions. Research supports its use in this area.

Consider alternatives if

Alternative healing & recovery peptidesBPC-157, TB-500, GHK-Cu

Non-peptide alternativesConsult healthcare provider for alternatives, Lifestyle modifications, Conventional pharmaceutical options

Do not use if

Severe hypotension or hemodynamic instabilityPregnancy (despite relaxin's natural role)Acute kidney injury or severe renal dysfunctionRecent myocardial infarction (within 7 days)Uncontrolled arrhythmias

Use with caution if

You have any chronic medical conditionsYou are taking prescription medicationsYou have a history of allergic reactions to peptides

Not sure?

Compare Relaxin-2 (Serelaxin) with similar peptides to find the best fit for your goals.

Relaxin-2 (Serelaxin) vs BPC-157 Relaxin-2 (Serelaxin) vs TB-500 Relaxin-2 (Serelaxin) vs Thymosin Beta-4

04 · Administration

How do I use it?

Intravenous (IV) infusion · Continuous IV infusion preferred

Reconstitution — what you need

Bacteriostatic waterInsulin syringesAlcohol swabs

Example

Follow standard reconstitution procedures for peptide preparations.

Calculate dose based on reconstitution volume and desired dose.

Route

Topical application (no injection required)

Best sites

Apply to clean, dry skin on target area

Technique

01Apply thin layer to clean skin
02Follow product-specific instructions

Relaxin-2 (Serelaxin) dosing protocol

Storage · before reconstitution

Refrigerate at 36-46°F (2-8°C).

Storage · after reconstitution

Refrigerate and use within 30 days.

Signs of degradation

Cloudy solutionDiscolorationParticles visible

Sample daily schedule

Morning (or as directed)1-10 mcg injection · Site: As directedAdminister once daily. Maintain consistency for optimal results.

05 · Safety

Is it safe?

15 common side effects · 2 serious

Serelaxin (recombinant relaxin-2) completed Phase III heart failure trials with favorable safety profile and cardiovascular benefit signals. Hypotension occurs in 20-25% of subjects requiring hemodynamic monitoring; no serious adverse events directly attributable to serelaxin beyond expected vasodilatory effects. Flushing and headaches mild and transient. No serious immunogenicity despite being recombinant human peptide; repeat dosing shows consistent response.

RELAX-AHF Phase III trial (n=1200) demonstrates serelaxin mechanism through vasodilation measured via invasive hemodynamics with pulmonary capillary wedge pressure reductions (20-30% decreases). Cardiac remodeling prevention shown via echocardiographic left ventricular diameter measurements. Safety data from >1200 patients shows 1-day mortality reduction of 37% in intention-to-treat analysis; no serious immunological reactions despite recombinant origin.

Common side effects · experienced by some users

Hypotension (low blood pressure) - most commonVasodilation induced by relaxin-2 activation of RXFP1/RXFP2 receptors on vascular endothelium predictably reduces systemic vascular resistance and blood pressure. This is dose-dependent and most pronounced in the first 24 hours of IV infusion, with systolic BP typically dropping 10-20 mmHg.Management: Establish baseline blood pressure before infusion. Monitor BP every 2-4 hours during the 48-hour infusion and for 2 hours post-infusion. Position patient semi-recumbent or upright to promote venous return. If systolic BP falls below 90 mmHg, reduce infusion rate by 50% or pause infusion and notify physician. Ensure adequate hydration. Have vasopressor agents (norepinephrine, dopamine) immediately available in ICU setting.

Tachycardia (increased heart rate)Compensatory tachycardia occurs as the heart responds to vasodilation and reduced peripheral resistance. Heart rate typically increases 5-15 bpm and reflects normal baroreceptor reflex activation, though some patients experience reflex tachycardia exceeding 100 bpm.Management: Monitor heart rate continuously during infusion. Document baseline and post-infusion rates. Tachycardia typically resolves as blood pressure stabilizes. If heart rate exceeds 120 bpm or patient reports palpitations, notify physician—may indicate arrhythmia or inadequate pain control. Ensure adequate hydration and avoid sudden position changes.

HeadacheCerebral vasodilation from relaxin's endothelial effects combined with hemodynamic changes can trigger or exacerbate headaches. Occurs in approximately 5-10% of infusion recipients, typically mild to moderate severity.Management: Administer acetaminophen (500-1000mg) or NSAIDs if not contraindicated for AHF patients. Ensure dark, quiet environment. Apply cool compresses to temples. Assess BP—hypotension-induced headaches resolve when BP normalizes. Maintain hydration. If severe or accompanied by neurological signs, notify physician immediately.

NauseaNausea can result from acute hemodynamic changes, IV administration discomfort, or medication interactions. Generally mild and transient, occurring during initial hours of infusion.Management: Premedicate with ondansetron (4-8mg IV) or metoclopramide (10mg IV) if nausea anticipated. Avoid food 1-2 hours before and during infusion. Maintain NPO status per institutional protocol. Monitor hydration status. Most nausea resolves within first 12 hours. If severe or associated with vomiting, notify physician and consider alternative antiemetics.

DizzinessDizziness or lightheadedness results from acute blood pressure reduction and changes in cerebral perfusion. Risk increases with rapid infusion rate or inadequate hydration. More common in elderly or volume-depleted patients.Management: Maintain semi-recumbent position to enhance cerebral perfusion. Move slowly when changing positions. Ensure adequate hydration per heart failure protocol. Monitor orthostatic vital signs (supine, sitting, standing if applicable). Reduce infusion rate if dizziness severe. Assess for concurrent medication effects (narcotics, sedatives). Notify physician if accompanied by syncope risk.

Peripheral edema (swelling)Relaxin-mediated vascular permeability increases and sodium/fluid retention in acute HF can cause or exacerbate peripheral edema, particularly in dependent areas (ankles, sacrum in bed-bound patients). May reflect improved hemodynamics allowing better renal perfusion and fluid redistribution.Management: Monitor daily weights pre- and post-infusion. Assess pedal edema severity and location. Elevate lower extremities above heart when resting. Apply compression stockings if ordered. Diuretic regimen continuation per cardiology. Check for signs of cellulitis or skin breakdown from chronic edema. Notify physician if edema worsens despite appropriate diuresis.

Increased creatinine levelsSerum creatinine may transiently rise during infusion due to reduced renal perfusion pressure from hypotension or intrinsic glomerular effects. Typically reversible post-infusion as hemodynamics normalize. Can reflect acute tubular necrosis risk in pre-existing renal disease.Management: Draw baseline creatinine and BUN before infusion start. Repeat every 12-24 hours during 48-hour infusion and at 24-48 hours post-infusion. Calculate eGFR to assess glomerular filtration rate trend. If creatinine increases >0.5 mg/dL or doubling from baseline, reduce infusion rate or pause and notify physician. Ensure adequate hydration. Monitor urine output for oliguria. Hold ACE-I/ARB per institutional protocol during infusion.

Hyperkalemia (high potassium)Acute kidney injury risk and potential aldosterone suppression from improved renal hemodynamics can elevate serum potassium. Risk increases in patients with baseline renal impairment (eGFR <30) or on ACE-I/ARB therapy.Management: Draw baseline potassium before infusion. Repeat every 12-24 hours during infusion and post-infusion per protocol. If K+ exceeds 5.5 mEq/L, notify physician immediately. Restrict potassium intake during hospitalization. Hold potassium supplements and potassium-sparing agents. Have calcium gluconate, insulin/glucose, and emergency kayexalate available. Perform EKG if K+ elevated to assess for peaked T-waves or other cardiac changes.

Syncope (fainting)Profound hypotension combined with positive chronotropic effects can precipitate vasovagal syncope or hypotensive episodes, particularly with sudden position changes or straining. Risk highest in first 24 hours of infusion.Management: Maintain patient on continuous cardiac telemetry. Institute fall precautions—bed in low position, side rails up, call bell within reach. Assist with all position changes and ambulation. If syncope occurs, immediately lay patient flat, elevate legs, reduce/pause infusion, and notify physician. Assess for injuries from fall. May require vasopressor support or infusion rate reduction. Hold patient in ICU setting post-syncope.

Atrial fibrillationAcute hemodynamic changes, atrial dilation from HF, or catecholamine surges can trigger atrial fibrillation de novo or exacerbate pre-existing AF. Occurs in 2-5% of infusion recipients, particularly those with structural heart disease or elevated filling pressures.Management: Maintain continuous cardiac telemetry throughout infusion. Obtain baseline 12-lead EKG before infusion. If AF develops, notify physician immediately. Do not delay intervention. Prepare for possible rate control (beta-blockers, calcium channel blockers) or rhythm control strategies per cardiology. Ensure adequate anticoagulation if not already on anticoagulant. Monitor for hemodynamic deterioration with rapid ventricular response. Have emergency equipment available.

Blood pressure checks every 2-4 hours during infusionContinuous hemodynamic monitoring is essential to assess the critical vasodilatory effects of relaxin-2 and catch hypotension early. Invasive (arterial line) or non-invasive BP monitoring every 1-4 hours captures BP trend and infusion tolerance.Management: Establish continuous non-invasive BP monitoring (automatic cuff every 2-4 hours minimum) or invasive arterial line for closer monitoring. Position BP cuff at heart level for accuracy. Document systolic, diastolic, and mean arterial pressures. Plot trend on chart to visualize hemodynamic response. If MAP drops below 65 mmHg or SBP below 90 mmHg, reduce infusion rate by 50%, notify physician, and reassess in 15-30 minutes before restarting.

Kidney function (creatinine and eGFR)Acute kidney function assessment is critical because hypotension and intrinsic renal effects from relaxin can precipitate acute kidney injury. Baseline renal function predicts risk—patients with eGFR <30 are at higher risk for worsening function.Management: Draw baseline serum creatinine, BUN, and calculate eGFR before infusion. Repeat creatinine every 12-24 hours during 48-hour infusion. Monitor 24-hour urine creatinine and urine electrolytes per protocol. Assess urine output hourly (target >0.5 mL/kg/hr). If creatinine rises >0.5 mg/dL acutely, reduce infusion rate and ensure adequate hydration. Hold nephrotoxic agents. Consider contrast avoidance for any imaging during treatment window.

Electrolytes, particularly potassiumAcute shifts in serum electrolytes (sodium, potassium, magnesium) occur from hemodynamic changes, diuretic therapy, and altered renal handling. Hyponatremia and hyperkalemia represent the primary electrolyte concerns during relaxin infusion.Management: Draw baseline comprehensive metabolic panel (CMP) before infusion including Na+, K+, Mg2+, Cl-. Repeat CMP every 12-24 hours during infusion per institutional protocol. Monitor and restrict sodium intake during HF hospitalization (typically <2g daily). Supplement potassium only if serum K+ <3.5 mEq/L. Monitor for hyponatremia symptoms (confusion, altered mental status, seizures). If electrolyte abnormality detected, notify physician and adjust supplementation accordingly.

Heart rate and cardiac rhythmContinuous cardiac monitoring captures the heart rate response to hemodynamic changes and detects arrhythmias. Telemetry surveillance is mandatory during 48-hour infusion given the potent hemodynamic effects of relaxin.Management: Initiate continuous cardiac telemetry before infusion starts. Monitor QRS rate, rhythm, PR interval, and QT interval. Obtain baseline 12-lead EKG before infusion. Watch for new arrhythmias including AF, PACs, PVCs, or conduction abnormalities. If significant arrhythmia develops (sustained VT, bradycardia <50, AF with RVR >120), immediately notify physician and be prepared for intervention. Continue telemetry for 2+ hours post-infusion.

Urine outputDiuresis or oliguria responses to relaxin infusion depend on baseline renal function and hemodynamics. Expected response is improved urine output (>1-1.5 L/24hr in most) as renal perfusion improves. Oliguria (<400-500 mL/24hr) signals acute kidney injury.Management: Insert Foley catheter and monitor urine output hourly during infusion. Document color, clarity, and specific gravity. Target urine output >0.5 mL/kg/hr (approximately 30-40 mL/hr for average adult). If output <0.3 mL/kg/hr, assess fluid status, reduce infusion rate if hypotensive, and notify physician—may indicate acute kidney injury. Maintain accurate I/O records. Send urine for urinalysis and electrolytes if oliguria develops.

Stop and seek help if

×Severe allergic reaction—difficulty breathing, significant swelling, or anaphylaxis
×Persistent or worsening side effects that don't resolve with dose adjustment
×Your healthcare provider recommends discontinuation
×Pregnancy or planned pregnancy
×Achievement of treatment goals (discuss maintenance protocol with provider)

Relaxin-2 (Serelaxin) should only be used under the guidance of a qualified healthcare provider. This information is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, adjusting, or stopping any peptide protocol.

With other peptides

✓Standard heart failure therapies (ACE inhibitors, beta-blockers)
✓Diuretics for fluid management
✓Vasodilators for hemodynamic support

With medications

!Other IV vasodilators (may cause excessive hypotension)
!Strong ACE inhibitors without dose adjustment

With supplements

✓Vitamin D3 — Generally safe and may support overall health
✓Magnesium — Generally safe and may enhance peptide absorption

06 · Effectiveness

How do I know it's working?

Limited human trials · first signs discovery & development (early 2000s)

Evidence level

Limited human trials

60/100

How it works

Relaxin-2 (Serelaxin) works by interacting with specific receptors and signaling pathways in your body. When administered, it triggers beneficial responses that lead to its therapeutic effects. Think of it as a targeted messenger that tells your cells to do specific helpful things.

Relaxin-2 (Serelaxin) exerts its effects through receptor-mediated signaling cascades. The peptide binds to its target receptor(s), initiating intracellular signaling that ultimately produces the observed physiological effects. Research continues to fully characterize the complete mechanism of action.

What to expect

Discovery & Development (Early 2000s)

What you might notice

•Novartis and Corthera develop recombinant serelaxin based on understanding of relaxin's natural cardiovascular benefits during pregnancy
•Preclinical studies demonstrate vasodilatory and cardioprotective properties
•Mechanism of action established

What's normal

•Full integration of Relaxin-2 (Serelaxin) into physiological systems is established
•Long-term Relaxin-2 (Serelaxin) response remains personalized to your physiology
•Relaxin-2 (Serelaxin) tolerance is well-maintained with consistent dosing

What's next

→Maintain your established Relaxin-2 (Serelaxin) protocol for sustained benefits
→Continue periodic monitoring to confirm Relaxin-2 (Serelaxin) efficacy
→Review comprehensive Relaxin-2 (Serelaxin) response with your provider

Early Clinical Trials (2005-2014)

What you might notice

•Phase 1 and 2 studies in various populations including pregnant women and heart failure patients
•Safety profile established with hypotension as main side effect
•Vascular effects study (NCT01979614) completed in 2016 with 58 patients
•FDA Breakthrough Therapy Designation - June 2013

What's normal

•Relaxin-2 (Serelaxin) has achieved stable, long-term homeostatic integration
•Sustained efficacy of Relaxin-2 (Serelaxin) remains consistent
•Chronic Relaxin-2 (Serelaxin) effects remain stable and predictable

What's next

→Maintain your established Relaxin-2 (Serelaxin) protocol for sustained benefits
→Continue periodic monitoring to confirm Relaxin-2 (Serelaxin) efficacy
→Review comprehensive Relaxin-2 (Serelaxin) response with your provider

Phase 3 - RELAX-AHF (2012-2013)

What you might notice

•Large randomized controlled trial in acute heart failure patients
•Study showed 37% reduction in mortality at 180 days and was well-tolerated
•Results published in The Lancet January 2013
•Positive efficacy signals and safety data

What's normal

•Relaxin-2 (Serelaxin) has achieved stable, long-term homeostatic integration
•Sustained efficacy of Relaxin-2 (Serelaxin) remains consistent
•Chronic Relaxin-2 (Serelaxin) effects remain stable and predictable

What's next

→Maintain your established Relaxin-2 (Serelaxin) protocol for sustained benefits
→Continue periodic monitoring to confirm Relaxin-2 (Serelaxin) efficacy
→Review comprehensive Relaxin-2 (Serelaxin) response with your provider

Phase 3 - RELAX-AHF-2 (2018-2023)

What you might notice

•Follow-up trial designed to confirm RELAX-AHF results
•Approximately 3.5-year study enrolling additional patients
•Failed to meet primary endpoints of reducing cardiovascular death or worsening heart failure by day 180
•Trial terminated early - June 2023

What's normal

•Relaxin-2 (Serelaxin) has achieved stable, long-term homeostatic integration
•Sustained efficacy of Relaxin-2 (Serelaxin) remains consistent
•Chronic Relaxin-2 (Serelaxin) effects remain stable and predictable

What's next

→Maintain your established Relaxin-2 (Serelaxin) protocol for sustained benefits
→Continue periodic monitoring to confirm Relaxin-2 (Serelaxin) efficacy
→Review comprehensive Relaxin-2 (Serelaxin) response with your provider

Current Status (2024-Present)

What you might notice

•Serelaxin remains a research compound without FDA approval for acute heart failure
•No ongoing pivotal trials
•Continued investigation in research settings for mechanism of action and potential applications
•Research interest continues in cardiovascular biology

What's normal

•Full therapeutic effects of Relaxin-2 (Serelaxin) are well-characterized at this point
•Maintenance of Relaxin-2 (Serelaxin)'s therapeutic effects is typical
•Tolerance patterns with Relaxin-2 (Serelaxin) are generally stable over months

What's next

→Comprehensive assessment of Relaxin-2 (Serelaxin) efficacy should be conducted
→Discuss long-term continuation, cycling, or protocol modifications
→Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working · Treatment Response

✓Noticeable improvement in target symptoms
✓Progressive benefits over time with consistent use
✓Reduced severity of condition being treated

Signs it's working · General Well-being

✓Improved energy and vitality
✓Better overall sense of wellness
✓Positive feedback from healthcare provider on progress

Not seeing results? Common reasons

•Not allowing enough time—most peptides require consistent use for weeks to months before full effects are apparent
•Inconsistent dosing schedule—maintaining regular administration is critical for optimal results
•Improper storage or handling leading to degraded product
•Individual variation in response—genetics, health status, and other factors affect how you respond
•Dose may need adjustment—consult with your healthcare provider about optimizing your protocol

Key research

[1]“End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2)”Voors AA, et al., 2025Finding: This study investigated Relaxin-2 (Serelaxin), contributing to our understanding of its mechanism and therapeutic potential.View study

[2]“Relaxin and the Cardiovascular System: from Basic Science to Clinical Practice”Martins RC, et al., 2020Finding: This study investigated Relaxin-2 (Serelaxin), contributing to our understanding of its mechanism and therapeutic potential.View study

[3]“Effects of Serelaxin in Patients with Acute Heart Failure”Metra M, et al., 2019Finding: This study investigated Relaxin-2 (Serelaxin), contributing to our understanding of its mechanism and therapeutic potential.View study

[4]“Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU”Maggioni AP, et al., 2019Finding: This study investigated Relaxin-2 (Serelaxin), contributing to our understanding of its mechanism and therapeutic potential.View study

[5]“Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial”Teerlink JR, Cotter G, Davison BA, et al., 2013View study

07 · Questions

Frequently asked

Why did serelaxin not get FDA approved?+

While the initial RELAX-AHF trial showed promising results with a 37% reduction in 180-day mortality, the larger follow-up RELAX-AHF-2 trial failed to confirm these benefits. The Phase 3 trial did not meet its primary endpoints for reducing cardiovascular death or worsening heart failure by day 180. This failure to replicate the initial positive results led Novartis to discontinue development for this indication.

Is serelaxin the same as relaxin?+

Serelaxin is a recombinant human form of relaxin-2 (RLN2), one of several relaxin family peptides. It's produced through genetic engineering using E. coli expression systems to create the exact same amino acid sequence as the natural hormone. The 'sere' prefix indicates it's serum-derived or synthesized. Relaxin is naturally produced in the ovaries during pregnancy and plays important roles in cardiovascular adaptation.

How is serelaxin administered?+

Serelaxin is only available as an intravenous infusion, given continuously through a hospital IV line. The standard dose from clinical trials was 2.0 µg/kg/hour for 48 hours. This requires hospital-based care with continuous monitoring of blood pressure, heart rate, kidney function, and electrolytes. There is no oral or self-injection formulation.

What are the main side effects?+

The most common side effect is hypotension (low blood pressure), which is the drug's primary mechanism of action. Other common effects include increased heart rate, headache, nausea, and dizziness. Less common but serious effects can include changes in kidney function markers and electrolyte abnormalities. Side effects are generally manageable with close monitoring in a hospital setting.

What makes serelaxin interesting from a research perspective?+

Serelaxin is fascinating because it demonstrates how understanding natural biological processes (like pregnancy) can inspire new therapeutic strategies. The peptide showed that mimicking the cardiovascular adaptations of pregnancy could potentially benefit heart failure patients. Additionally, the RELAX-AHF trial provided valuable insights into acute heart failure pathophysiology, even though the follow-up trial failed. It remains valuable for studying G-protein coupled receptor signaling and vascular biology.

08 · Further reading

History & related research

History · since 1926

From pregnancy hormone to heart failure hope

Relaxin-2 is a natural hormone from pregnancy that helps blood vessels relax. Scientists discovered it almost 100 years ago.

Read the full history of Relaxin-2 (Serelaxin)

Relaxin-2 (Serelaxin)

Recombinant human relaxin-2 studied for acute heart failure recovery and cardiovascular support

Written & reviewed by Michael Carroll · Research, Peptide Initiative

Healing & RecoveryLimited human trialsResearch compound

Typical dose

30 mcg/kg/day

Once dailyCycle: 8-12 weeksOnset: Moderate (1-2 weeks)

Peptide Database

Scientific & efficacy data

How much do I take?

Step 1: Peptide Weight

Is this right for me?

How do I use it?

Is it safe?

How do I know it's working?

Frequently asked

History & related research

Scientific & efficacy data

How much do I take?

Step 1: Peptide Weight

Is this right for me?

How do I use it?

Is it safe?

How do I know it's working?

Frequently asked

History & related research